

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: D. L. Linemeyer et al.

Serial No. 10/007,343

Filed: October 22, 2001

For: DNA ENCODING BRADYKININ B1  
RECEPTOR

Art Unit: \_\_\_\_\_

Examiner: \_\_\_\_\_

Assistant Commissioner for Patents  
Washington, D.C. 20231INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application.

This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).


2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK &amp; CO., INC.

By

  
Rec No. 36,545

Date

5/14/02



# INFORMATION DISCLOSURE STATEMENT

4. Copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:


U. S. SERIAL NUMBER	RELATED APPLICATION	
	FILING DATE	MERCK CASE

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to a first Official Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after receipt of the first Office Action on the merits, but before Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

  
By: J. Mark Hand

Attorney \_\_\_\_\_ For Applicant(s)

Reg. No. 36,545

MERCK & CO., INC.


Patent Dept., RY60-30,

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 3905

Date: MAY 14, 2002



PATENT

Sheet 1 of 4

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)ATTY. DOCKET NO.  
19202 DBSERIAL NO.  
10/007,343APPLICANT(S)  
LINEMEYER, DAVID ET AL.

FILING DATE

10/22/01

GROUP ART UNIT

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,712,111	1/27/98	Linemeyer et al.			
	5,965,367	10/12/99	Linemeyer et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	A	Perkins, Martin N. et al., Antinociceptive activity of the bradykinin B1 and B2 receptor antagonists, des-Arg <sup>9</sup> , [Leu <sup>8</sup> ]-BK and HOE 140, in two models of persistent hyperalgesia in the rat, Pain, Vol. 53, p. 191-197, 1993.
	B	McEachern, Adrienne E., et al., Expression cloning of a rat B2 bradykinin receptor, Proc. Natl. Acad. Sci. USA, Vol. 88, p. 7724-7728, 1991.
	C	Burch and Axelrod, Dissociation of bradykinin-induced prostaglandin formation from phosphatidylinositol turnover in Swiss 3T3 fibroblasts: Evidence for G protein regulation of phospholipase A2.


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 19202 DB		SERIAL NO. 10/007,343	
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				APPLICANT(S) D. L. LINEMEYER ET AL.			
				FILING DATE 10/22/01		GROUP ART UNIT	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
		D		Strader, Catherine et al., Structural basis of B-adrenergic receptor function, The FASEB Journal, Vol. 3, p. 1825-1832, 1989.			
		E		Chartrain, Nicole et al., Molecular Cloning, Structure, and Chromosomal Localization of the Human Inducible Nitric Oxide Synthase Gene, The Journal of Biological Chemistry, Vol. 269, No. 9, p. 6765-6772, 1994.			
		F		Rinas, Ursula, et al., Characterization of Recombinant Factor XIIIa Produced in Saccharomyces Cerevisiae, Biotechnology, p. 543-546, 1990.			
		G		Perkins & Kelly, Induction of bradykinin B1 receptors in vivo in a model of ultra-violet irradiation-induced thermal hyperalgesia in the rat, Br. J. Pharmacol., Vol. 110, p. 1441-1444, 1993.			
		H		Schneck, Kathryn, et al., Bradykinin B1 receptors in rabbit aorta smooth muscle cells in culture, European J. of Pharmacol., Vol. 266, p. 277-282, 1994.			
		I		Tropea, Margaret et al., B1 and B2 kinin receptors on cultured rabbit superior mesenteric artery smooth muscle cells: receptor-specific stimulation of inositol phosphate formation and arachidonic acid release by des-arg-bradykinin and bradykinin, Journal of Pharmacol. and Experimental Therapeutics, Vol. 264, No. 2, p. 930-937, 1993.			
		J		Horowitz, Burton et al., Synthesis and Assembly of Functional Mammalian Na, K-ATPase in Yeast, Journal of Biological Chemistry, Vol. 265, No. 8, p. 4189-4192, 1990.			
		K		Goldstein & Wall, Activation of Protein Formation and Cell Division by Bradykinin and Des-Arg9-bradykinin, The Journal of Biological Chemistry, Vol. 259, No. 14, p. 9263-9268, 1984.			
		L		Slivka and Insel, Phorbol Ester and Neomycin Dissociate Bradykinin Receptor-mediated Arachidonic Acid Release and Polyphosphoinositide Hydrolysis in Madin-Darby Canine Kidney Cells, Journal of Biological Chemistry, Vol. 263, No. 29, p. 14640-14647, 1988.			
		M		Phillips, Elsa et al., Expression of Functional Bradykinin Receptors in Xenopus Oocytes, Journal of Neurochemistry, Vol. 58, No. 1, p. 243-249, 1992.			
		N		Regoli and Barabe, Pharmacology of Bradykinin and Related Kinins, Pharmacological Reviews, Vol. 32, No. 1, p. 1-46, 1980.			
		O		Masu, Yasuo et al., cDNA cloning of bovine substance-K receptor through oocyte expression system, Nature, Vol 329, p. 836-838, 1987.			
		P		Dray and Perkins, Bradykinin and inflammatory pain, J. Neurophysiol., Vol. 63, p. 256-272, 1993.			
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 19202DB		SERIAL NO. 10/007,343	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT(S) D. L. LINEMEYER ET AL.			
				FILING DATE 10/22/01		GROUP ART UNIT	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Q	Couture, R. et al., Peptides and the human colon: an in vitro pharmacological study, Can. J. Physiol. Pharmacol., Vol. 59, p. 957-964 1981.					
	R	Wirth, Klaus et al., DesArg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (desArg10-[Hoe140]) is a potent bradykinin B1 receptor antagonist, European Journal of Pharmacology, Vol. 205, p. 217-218, 1991.					
	S	Regoli, Domenico et al., Conversion of kinins and their antagonists into B1 Receptor activators and blockers in isolated vessels, European Journal of Pharmacology, Vol. 127, p. 219-224, 1986.					
	T	Regoli, D. et al., Receptors for bradykinin in rabbit aortae, Can. J. Physiol. Pharmacol., Vol. 55, p. 855-867, 1977.					
	U	Regoli, D. et al., De novo formation of vascular receptors for bradykinin1, Can. J. Physiol. Pharmacol., Vol. 56, p. 674-677, 1978.					
	V	Regoli, Domenico et al., Induction of B1-Receptors for kinins in the rabbit by a bacterial lipopolysaccharide, European Journal of Pharmacology, Vol. 71, p. 105-115, 1981.					
	W	Farmer, S.G. et al., Induction of vascular smooth muscle bradykinin B1 receptors in vivo during antigen arthritis, Agents and Actions, Vol. 34, p. 191-193, 1991.					
	X	deBlois, Denis et al., Effect of glucocorticoids, monokines and growth factors on the spontaneously developing responses of the rabbit isolated aorta to des-Arg9-bradykinin, Br. J. Pharmacol., Vol. 93, p. 969-977, 1988.					
	Y	deBlois, Denis et al., Pulse exposure to protein synthesis inhibitors enhances vascular responses to des-Arg9-bradykinin: possible role of interleukin-1, Br. J. Pharmacol. Vol. 103, p. 1057-1066, 1991.					
	Z	deBlois, Denis et al., Pharmacological modulation of the up-regulated responses to des-Arg9-bradykinin in vivo and in vitro, Immunopharmacology, Vol. 17, p. 187-198, 1989.					
	AA	Burch, R.M. et al., The Kallikrein-kininogen-kinin system in chronic inflammation, Agents and Actions, Vol. 27, 3/4, p. 258-260, 1989.					
	AB	Tiffany and Burch, Bradykinin stimulates tumor necrosis factor and interleukin-1 release from macrophages, Vol. 247, No. 2, p. 189-192, 1989.					
	AC	Proud, David, Kinin formation: Mechanisms and role in inflammatory disorders, Ann.Rev.Immunol., Vol. 6: p. 49-83, 1988.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 19202DB		SERIAL NO. 10/007,343	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANT(S) D. L. LINEMEYER ET AL.			
				FILING DATE 10/22/01		GROUP ART UNIT	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AD 1	Rhaleb, N. et al., Receptors for kinins in isolated arterial vessels of dogs, European Journal of Pharmacology, Vol. 162, p. 419-427 (1989).					
	AE 1	Lortie, Mark et al., The role of B1- and B2-kinin receptors in the renal tubular and hemodynamic response to bradykinin, American Physiological Society, Vol. 262, p. R72-R76, 1992.					
	AF 1	Powell, Steven J. et al., Human Bradykinin B2 Receptor: Nucleotide Sequence Analysis and Assignment to Chromosome 14, Genomics, Vol. 15, p. 435-438, 1993.					
	AG 1	Hess, Fred J. et al., Cloning and Pharmacological Characterization of a Human Bradykinin (BK-2) Receptor, Biochemical and Biophysical Research Communications, Vol. 184, No. 1, p. 260-268, 1992.					
	AH 1	Eggerickx, Dominique et al., Molecular Cloning, Functional Expression and Pharmacological Characterization of a Human Bradykinin B2 Receptor Gene, Vol. 187, No. 3, p. 1306-1313, 1992.					
	AI 1	Giladi and Spindel, Simple Luminometric Assay to detect Phosphoinositol-Linked Receptor Expression in Xenopus Oocytes, Vol. 10, No. 6, p. 744-747, 1991.					
	AJ 1	Hock, F.J. et al., Hoe 140 a new potent and long acting bradykinin-anagonist: in vitro studies, J. Pharmacol., Vol. 102, p. 769-773, 1991.					
	AK 1	Sandberg, Kathryn et al., Calcium mobilization by angiotensin II and neurotransmitter receptors expressed in Xenopus laevis oocytes, FEBS Letters, Vol. 241, No. 1,2 p. 177-180, 1988.					
	AL 1	Huang, Ruey-Ruey C., et al., Identification of Allosteric Antagonists of Receptor-Guanine Nucleotide-Binding Protein Interactions, Molecular Pharmacology, Vol. 37, p. 304-310, 1989.					
	AM 1	Kitts, Paul A. et al., Linearization of baculovirus DNA enhances the recovery of recombinant virus expression vectors, Nucleic Acids Research, Vol. 18, No. 19, 1990.					
	AN 1	Hess, Fred J. et al., Differential Pharmacology of Cloned Human and Mouse B2 Bradykinin Receptors, Molecular Pharmacology, Vol. 45, p. 1-8, 1993.					
	AO 1	McIntyre et al. 'Cloned Murine Bradykinin Receptor Exhibits... Selectivity', Mol Pharmacol. Vol 44, pp 346-355 (1992)					
	AP 1	Webb et al. 'B1 and B2 Bradykinin...mRNAs', J. of Neurochemistry, Vol. 62, No. 4, pp 1247-1253 (1994)					
	AQ 1	Menke et al. 'Expression Cloning..Bradykinin Receptor', J. of Biol. Chem. Vol 269, No. 34 pp21583-21586 (1994)					
	AR 1	Atassi 'Preparation of Monoclonal Antibodies...Regions', Meth. in Enzym. Vol 121, pp 69-95 (1986)					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							